Edwin H. Kim, MD: Safety Data, Implications of New Oral Immunotherapy ADP101

News
Video

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

In this part of his interview with the HCPLive editorial team, Edwin H. Kim, MD, went into the safety data and implications for food allergy patients following the phase 1/2 Harmony study on ADP101, an investigational multi-allergen oral immunotherapy (OIT).

Kim serves as an associate professor of pediatrics at University of North Carolina’s School of Medicine. The data he discussed on ADP101 had been presented at the 2023 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology (ACAAI).

“I mean, I think this is just going to give another sort of tool for us in the clinic to be able to consider for these patients, especially the ones that are going to be allergic to more than 1 food, to be able to have something that might be able to make them less reactive,” Kim said. “Can it get to the point where they can freely eat these foods? Well, that we still need to figure out at this point. We don't know that from this data. But this does seem to suggest that we can make people less reactive to either the one or the many foods that they may be allergic to.”

Later, Kim was asked about what implications these new findings have for the treatment of pediatric patients with food allergies.

“Yeah, so I think this product is great, and it's going to address that patient that might be allergic to multiple foods or foods that are not peanut, of course,” Kim said. “…But again, this is sort of a medication you would use in combination with still trying to overall avoid that food. But the next generation of treatments we'd really be thinking about, ‘Okay, how do we go beyond just protecting? How do we actually get to the point where someone is not allergic where they can actually eat the food, introduce it sort of fully into their diet?’

He then noted that this represents a high bar for the future.

“This study and others have proven to the point that I think we can make sort of short term differences to the immune system, protect our folks and now we have to really push the envelope to get to the point where we can start talking about tolerance and cure,” Kim said.

To find out more about the data presented, view the full interview posted above.

Dr. Kim was PI of the UNC site within the Harmony Study. He does not have any personal financial conflicts with Alladapt who sponsored the study.

The quotes contained in this discussion were edited for the purposes of clarity.

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
© 2024 MJH Life Sciences

All rights reserved.